Artios Pharma Limited’s US$153 Million Series C Financing

Goodwin Procter advised Omega Funds on the deal.Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company exploiting a broad DDR-based platform and small molecule…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Federica Tiefenthaler

Author: Federica Tiefenthaler

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here